ReCor Medical launches trial for Paradise renal denervation device

April 7, 2016 By Brad Perriello Leave a Comment

ReCor Medical said today that it’s enrolled the 1st patients in the 292-patient Radiance-HTN study of its Paradise renal denervation device for treating hypertension.

The blinded, randomized and sham-controlled trial is designed to evaluate the Paradise system in patients with essential hypertension taking 2 or fewer medications and patients with treatment-resistant hypertension on a minimum of 3 drugs. The trial has 2 arms: The Solo cohort is designed to evaluate the essential hypertension patients; the Trio cohort will study the treatment-resistant group, Palo Alto, Calif., and Amsterdam-based ReCor said.

“We are excited to have enrolled the first patient in this very important study,” Dr. Joost Daemen, who enrolled the 1st Trio patient at the Erasmus University Medical Center in Rotterdam, Holland, said in prepared remarks. “We have significant experience using the Paradise System and believe that the Radiance-HTN study is well designed to demonstrate the system’s treatment effect. If Radiance-HTN is positive, then, given the existing CE-marking, we would consider Paradise as an essential tool to treat patients with resistant hypertension here at Erasmus.”

“The Solo cohort represents a large population of hypertension patients, many of whom are seeking alternative methods to manage a lifetime of hypertension treatment,” added Dr. Pei-Hsiu Huang, who enrolled the 1st Solo patient at Sacramento’s Sutter Health. “We are excited to be part of this important study and by the possibility that Radiance-HTN could demonstrate the efficacy of renal denervation with the Paradise system, and open a path to new treatment options for our hypertension patients.”

ReCor won an investigation device exemption from the FDA for the trial in February. The company raised a $15 million Series D round back in April 2015 to fund the study of Paradise, which is designed to use ultrasound energy to ablate the nerve endings in the lining of the renal arteries.

ReCor, Boston Scientific (NYSE:BSX), St. Jude Medical (NYSE:STJ) and Medtronic (NYSE:MDT) are all back in the renal denervation game, 2 years after Medtronic announced its Symplicity-3 renal denervation device missed its primary endpoint. Boston Scientific delayed its Vessix program in immediate response, and St. Jude Medical (NYSE:STJ) suspended its own trial. Eventual Medtronic acquisition Covidien ceded the field entirely, winding down development of its OneShot renal denervation device, which already had E.U. regulatory approval, and closing its Rapid II trial.

But the same month that ReCor announced its Series D round, Medtronic launched a new RDN trial, aiming to settle the “confounding” issues raised during Symplicity-3. Boston Scientific is running 2 clinical programs for its Vessix device: The Reduce trial, evaluating Vessix in treating hypertension; and the Relieve series, evaluating the technology for other conditions, including end-stage renal disease, heart failure, atrial fibrillation and diabetes. And St. Jude is running trials of its EnligHTN device in hypertension.

FDA recommends limiting use of power morcellators
The FDA today recommended that laparoscopic power morcellators, which have been implicated in the spread of cancer, be limited to use with certain tissue containment systems and only in premenopausal women under 50 years of age. Power morcellators were used for 20 years to laparoscopically remove benign tumors of the uterus, known as fibroids, by… […]
Abilitech aims to arm people with independence
Some have dubbed Abilitech’s device “a wheelchair for the arms.” Its machined aluminum exoskeletal arm and breathable cloth vest use a spring counterbalance system and a “living hinge” that spreads the load, making it — and the arm — feel weightless. Nancy Crotti, Managing Editor Rob Wudlick brushed his teeth on his own recently for… […]
RJG Germany opens injection molding training facility
RJG Germany (Karlstein) recently opened a new training lab for injection molding. The facility consists of a classroom that seats up to 20 students and a fully equipped lab for hands-on experience. The technical center currently consists of a 60-ton injection molding machine from Yizumi Germany, temperature control units and a material drying system from… […]
Instron debuts two new universal testing systems
Instron (Norwood, Mass.) announced today that it is introducing a new generation of universal testing systems. The 3400 and 6800 Series are successors to the company’s 3300 and 5900 Series systems and are available in single- and dual-column models with capacities ranging from 500 N to 50 kN. Instron said it has added features and… […]
Medical tubing market to be worth $12 billion in 2025
The medical tubing market is expected to be worth $11.9 billion by 2025, according to an analysis from Grand View Research. Grand View Research suggests the industry will expand at a revenue-based consumer annual growth rate of 9.2% over the next five years. Increased health expenditures from individuals and increased emphasis on healthcare by the […]
How diaphragm pumps can work for sensitive devices
Diaphragm pumps work like bicycle pumps, with one intake and one output cycle per revolution of the drive motor, which produces an inherently pulsatile flow. Dynaflo developed one for the U.S. military that virtually eliminates this effect. Lorenzo Majno, Dynaflo Diaphragm pumps offer a number of features that could be valuable to designers of products… […]
MTD Micro Molding late president to be inducted into Plastics Hall of Fame
MTD Micro Molding this week announced that its late president, Dennis Tully, will be inducted into the Plastics Academy’s Plastics Hall of Fame. Tully is one of this year’s six posthumous inductees, who are elected by living members of the Hall of Fame following a screening process. “These new posthumous inductees proudly represent the length… […]
This neural implant can be both remotely charged and programmed
Engineers at Rice University’s Brown School of Engineering are touting the first neural implant capable of being programmed and charged remotely with a magnetic field. Kaiyuan Yang, Jacob Robinson, Zhanghao Yu and Joshua Chen collaborated to develop the integrated MagNI (magnetoelectric neural implant) microsystem, which could allow imbedded devices such as a spinal cord stimulator… […]
Integer shares up after Street-beating Q4
Integer Holdings (NYSE:ITGR) shares were up at close today on fourth-quarter results that topped the consensus forecast, despite a big dip in profits. The Plano, Texas-based company posted profits of $11 million, or 33¢ per share, on sales of $325.6 million for the three months ended Dec. 31, 2019, for a 57.2% bottom-line slide on sales… […]
These young medtech companies raised the most money in 2019
Medical device industry insiders may very well remember 2019 as the year that IPOs came back — but another sign that the U.S. economy has left the Great Recession far behind. Among the top investment deals in the space, half involved public offerings, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Total investments in… […]
Teleflex Medical OEM acquires medical tubing company
Teleflex Medical OEM (Wayne, Pa.), today announced the acquisition of IWG High Performance Conductors (HPC), a medical tubing and wire components manufacturer. The addition bolsters Teleflex Medical OEM’s position in the arena of custom-engineered medical devices and its ability to provide clients with technologies used in electrophysiology, drug- and stent-delivery and neurovascular interventions, according to… […]